Transgene and NEC extend Pact For Clinical Development of Cancer Vaccine

Transgen announced that they have signed an additional development cooperation agreement for personalized interventions. Neoantigen cancer vaccine TG4050. TG4050 is currently being evaluated in a randomized multicenter phase I trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers. Based on promising data obtained in this Phase I trial (new windowNCT04183166), Transgene and NEC are preparing a randomized phase I/II extension of this trial slated to start in 2024.

This new trial builds on compelling first signs of efficacy and induction of specific T-cell responses with the aim of generating a comprehensive set of immunological and clinical data to further demonstrate the potential of TG4050, as per pharmabiz.

TG4050 is built on Transgene's viral vector-based myvac platform and leverages NEC's cutting-edge AI technologies to identify and predict the most immunogenic neoantigens.

Alessandro Riva, chairman and CEO of Transgene, commented: "We are pleased to announce the extension of our agreement with NEC, which marks a significant milestone in our collaboration. We are looking forward to continuing to treat patients with our individualized cancer vaccine TG4050. The compelling initial phase I data presented with NEC at ASCO 2023 showed that all evaluable patients treated with TG4050 monotherapy developed a specific immune response and remained disease-free.

"Our joint clinical development plan builds on these promising data in a setting where there is no approved treatment to prevent patient relapse after adjuvant chemoradiotherapy. We believe that TG4050, by combining a powerful and immunogenic viral vector with an extremely sophisticated neoantigen selection tool, has the potential to address major medical needs in the adjuvant treatment of solid tumours."